{"schema_version":"secwatch.filing_event.v1","accession":"0001701541-24-000020","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.652902+00:00","generated_at":"2026-06-02T06:27:29.095405+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Black Diamond Q1 net loss $18.2M; cash $115.2M; Phase 2 BDTX-1535 data on track for Q3 2024","bullets":["Net loss of $18.2M for Q1 2024 vs $20.9M in Q1 2023; R&D exp $13.5M, G&A $6.7M.","Cash, equivalents, investments $115.2M as of Mar 31, 2024; runway into Q3 2025.","Phase 2 BDTX-1535 in 2L/3L EGFRm NSCLC initial data expected Q3 2024; 1L cohort enrollment ongoing, data Q1 2025.","ASCO June 1: Phase 1 BDTX-1535 GBM dose-escalation and window-of-opportunity trial results.","Board changes: Shannon Campbell and Prakash Raman appointed; Wendy Dixon and Alex Mayweg stepped down."],"urls":{"canonical":"https://secwatch.observer/filing/0001701541-24-000020","json":"https://secwatch.observer/filing/0001701541-24-000020.json","markdown":"https://secwatch.observer/filing/0001701541-24-000020.md","text":"https://secwatch.observer/filing/0001701541-24-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000170154124000020/0001701541-24-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000170154124000020/bdtx-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:27:29.095405+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"df5e3509cca2e6a94e3373dd4fba66daa005c001","claim":"Black Diamond Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income $18.2 million.","evidence_excerpt":"Net loss for the first quarter of 2024 was $18.2 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701541/000170154124000020/0001701541-24-000020-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"$18.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}